← all drugs
Rifampin Injection
in shortage · Anti-Infective · Snapshot: 2026-10-09
Day 2,060
of this shortage, counting from the FDA's first posting on 02/17/2021
- Manufacturers listed
- Mylan Institutional, a Viatris Company, Sanofi-Aventis U.S. LLC, Fresenius Kabi USA, LLC
- Reported reason(s)
- Demand increase for the drug; Other; Discontinuation of the manufacture of the drug
- Machine-readable
- JSON for this drug
Presentations (4)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| Rifampin, Injection, 600 mg (NDC 67457-445-60) | Mylan Institutional, a Viatris Company | Unavailable | 10/05/2026 |
| Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | unknown | 04/20/2026 |
| Rifampin, Injection, 600 mg (NDC 63323-351-20) | Fresenius Kabi USA, LLC | Limited Availability | 10/06/2026 |
| Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | Unavailable | 09/18/2026 |
History
Daily tracking of this drug began 2026-08-25 (the first day of the archive).
- 2026-09-10 — Rifampin Injection: availability wording revised for 1 presentation(s)
- 2026-08-27 — Rifampin Injection: availability wording revised for 1 presentation(s)
Each daily snapshot is compared with the one before it; status changes, availability-wording revisions, and arrivals or removals are listed here. A change the FDA makes and reverses between two snapshots is not seen. Every daily record is kept in the public repository.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.